PTS Diagnostics product discontinuation notice
May 13, 2026—The following customer bulletin about A1CNow+ Controls (REF 737) is published at the request of Nova-One Diagnostics.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Streck launches CD-Chex Daily flow cytometry control
May 12, 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories.
Roche to acquire PathAI for up to $1 billion
May 7, 2026—Roche has entered into a definitive merger agreement to acquire PathAI, extending a partnership that began in 2021 and expanded in 2024 to develop AI-based companion diagnostic algorithms.
Clarapath launches TrimStar Pro robotic microtomy system
May 5, 2026—Clarapath launched TrimStar Pro, an FDA-registered facing and trimming solution designed to help histology laboratories take a step toward automation.
Atellica TSTII Testosterone assay gets CDC HoSt-TT certification
May 4, 2026—Siemens Healthineers’ Atellica IM Testosterone II assay has achieved certification through the Centers for Disease Control and Prevention hormone standardization program for total testosterone, confirming that the Atellica IM TSTII immunoassay’s test results are equivalent to high-performance liquid chromatography coupled with tandem mass spectrometry.
Archimed Diagnostics, La Caisse acquire Stago
May 1, 2026—Archimed Diagnostics, part of private equity health care firm Archimed, has acquired Stago, with global investment group La Caisse participating as a minority shareholder.
Project Santa Fe Foundation partners with Vivica
April 24, 2026—Clinical Lab 2.0, an initiative of Project Santa Fe Foundation, is partnering with Life Data Lab, developer of Vivica LabReports, a laboratory platform that enables clinical labs to identify potential gaps in patient care (per provider request).
Omnia Inventa introduces LNL300 for lymph node retrieval
April 23, 2026—Omnia Inventa Medical has introduced the Lymph Node Locator 300, an FDA class I, 510(k)-exempt device designed to standardize lymph node retrieval from fatty tissue in oncologic specimens.
PathAI, MedStar Health partner to deploy AISight Dx
April 20, 2026—PathAI and MedStar Health announced a multiyear strategic collaboration to deploy PathAI’s AISight Dx digital pathology platform and AI algorithm products, including PathAI’s ArtifactDetect and TumorDetect, across MedStar’s network.
Labcorp launches FDA-cleared fentanyl test
April 16, 2026—Labcorp launched the Labcorp Fentanyl Urine Visual Test.